1. Antiaging and Prevention of Aging Associated Diseases
Associating Geroprotectors
Antiaging and Prevention of Aging Associated Diseases
Prof. Dr. E. Lasalvia-Prisco, C. Dau, P. Goldschmidt, F. Galmarini
Telemedical Organization, Montevideo, Uruguay

2. Background Methodology
Two drugs used in Medicine for many years are suspected to be geroprotectors, according to experimental research. Some clinical observations are compatible with extension of such geroprotective condition to humans.
Background
Methodology
Two drugs used in Medicine for many years are suspected to be geroprotectors, according to experimental research. Some clinical observations are compatible with extension of such geroprotective condition to humans
In this study, we reviewed the clinical records of 120 women 60/65 years old, who have consulted during 5 years. Forty, were under regular check-ups, with no other treatment; 40 received Metformin to treat their diabetes type 2 condition; and 40 received Metformin because they have also diabetes type 2 and Acetylsalicylic acid for cardiovascular preventive indication.
We reviewed the metabolic targets of these drugs to support their activity in prevention of aging associated diseases (see next slide), and also we have compared the variation of two parameters in blood chemistry that have been reported as markers of such activity. The mortality in the 3 groups in the observed 5 years was registered. 9 10

4. 120 people treated 5 years with low dose of metformin, acetylsalicylic acid or with both, have shown significant decrease of increment of glycosylated hemoglobin and ferritin observed in non-treated population. Mortality during the same 5 years was lesser in the treated groups.
Results NT M
MAA
12.4
5.2
4.0
Ferritin
5 years of increase (ng/ml )
400.8
305.2
288.6
Glycosylated Hemoglobin
5 years of increase (mg/dL)
5 years Mortality 24 15 11
NT: Non treated M: Metformin MAA: Metformin + Acetylsalicylic Acid

5. 5. Evaluation of Acetylsalicylic Acid Effect on Oxidative Stressed Mice BENKHASSI Zoubai et al. Int. J. Pure App. Biosci. 2 (6): (2014)
7. Aspirin Inhibits mTOR Signaling, Activates AMP-Activated Protein Kinase, and Induces Autophagy in Colorectal Cancer Cells. FARHAT V. N. DIN, et al. Gastroenterology June; 142(7): 1504–15
6. Chronic Inflammation (Inflammaging) and Its Potential Contribution to Age-Associated Diseases. Claudio Franceschi, and Judith Campisi. J Gerontol A Biol Sci Med Sci 2014 June; 69(S1): S4–S9
8. Aspirin reduces endothelial cell senescence. Stefanie M. Bode-Boger et al. Biochemical and Biophysical Research Communications 334 (2005) 1226–1232
1. Mitohormesis: promoting health and lifespan by increased levels of reactive oxygen species (ROS). Michael Ristow, Kathrin Schmeisser. Dose-Response, 12: 288–341, 2014
3. Immune-mediated antitumor effect by type 2 diabetes drug, metformin. Shingo Eikawa, PNAS. February 10, 2015 vol. 112 no. 6 : 1809–1814
2. New mechanisms of metformin action: Focusing on mitochondria and the gut. Kyu Yeon Hur, Myung-Shik Lee. J Diabetes Investig 2015; 6: 600–609
4. Metformin improves putative longevity effectors in peripheral mononuclear cells from subjects with prediabetes. A randomized controlled trial. S. Vigili de Kreutzenberg et al. Nutr Metab Cardiovasc Dis Jul; 25(7):
References
9. METFORMIN Can people with type 2 diabetes live longer than those without? A comparison of mortality in people initiated with metformin or sulphonylurea monotherapy and matched, non-diabetic controls. C. A. Bannister et al. Diabetes, Obesity and Metabolism (2014) 16: 1165–1173.
10. ACETYLSALICYLIC ACID The effect of low-dose daily aspirin intake on survival in the finnish centenarians cohort. Hedda Agüero-Torres et al. JAGS NOVEMBER 2001–VOL. 49, NO. 11: 1578